



## **Announcement from Ridgeview Instruments AB, provider of LigandTracer**

In March 2020, the World Health Organization (WHO) announced the outbreak of 2019-nCoV a pandemic. It also reported the 2019-nCoV as the first coronavirus to reach pandemic levels. Many researchers all over the world put a lot of efforts in finding out better ways for diagnosis, and prevention of the Corona virus disease (Covid-19) and most importantly discovering an effective treatment. Thus, a large number of articles have been published during last months. The studies have shown that sequence of 2019-nCoV RBD is similar to that of SARS-CoV suggesting that most probably 2019-nCoV uses ACE2 as its receptor. This means that currently available antibodies against SARS might be suitable for therapy of Covid-2019. Other strategy to battle this pandemic disease focuses on development of RNA or DNA based-vaccines and for cell delivery, lipid nanoparticles are usually used. LigandTracer technology can be used for characterization of [antibodies](#) and [nanoparticles](#) on live cells in real-time, as it has already been used for those purposes resulted in several publications in peer-reviewed journals. It is worth mentioning that our technology has also been used for understanding the interaction between [virus](#) and live cells. The LigandTracer real-time cell binding assays, on live cells, can provide crucial insight about binding kinetics and mechanism on the interaction between antibodies and virus, antibodies and cells, nanoparticles and cells as well as virus and cells.

During this critical time, we at Ridgeview would like to do everything we can to help researchers and other companies to find a way to overcome this problem. Thus, we would like to offer you a free of charge LigandTracer usage (time restricted depending on availability), If you are using any above-mentioned strategies to defeat Covid-2019. we will correspondingly be available to all clients by supporting all demos in Europe, answering questions or providing teaching, online. You are welcome to [contact us](#), If you are interested.